Research
Hormonal
Participants in the semaglutide group had a greater improvement in SF-36 physical-function score (mean change, 12.0 points) compared to the placebo group (mean change, 6.5 points; P<0.001).
Semaglutide may improve physical function in obese individuals with knee osteoarthritis.
StrongSupportsmedium confidence
Participants in the semaglutide group had a greater improvement in SF-36 physical-function score than those in the placebo group (mean change, 12.0 points vs. 6.5 points; P<0.001).
Why this rating
Based on a large randomized controlled trial design.
Source
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Henning Bliddal et al. · New England Journal of Medicine · 2024
DOI 10.1056/nejmoa2403664
rct · n=407Cited 306×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →